Clinical Trials · NCT00543218

PTH Comparison in Post Menopausal Women

CompletedPhase 3Teriparatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
63
Start date
Dec 2002
Locations
4 sites, Taiwan
Primary endpoint
To compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.
View Teriparatide compound reference